MyMD Pharmaceuticals, Inc. announced on June 14, 2024, as part of an agreed management change associated with the transactions contemplated by the Securities Purchase Agreement (SPA), the Company and Christopher Chapman, M.D. mutually agreed on the separation of Dr. Chapman from his position as President, Chief Medical Officer and member of the board of directors of the Company, effective as of June 14, 2024 (Effective Date). Dr. Chapman?s separation from the Company was amicable and was not the result of any disagreement between Dr. Chapman and the Company regarding any matter relating to the Company?s operations, policies, or practices. The separation will allow Dr. Chapman to focus more of his business time and attention on his work as Chairman and Chief Executive Officer of Telomir Pharmaceuticals, Inc. and its affiliates.

On June 13, 2024, the Company appointed Mitchell Glass, M.D., a current member of the board of directors of the Company, as president and chief medical officer, effective as of June 13, 2024. The Company also announced on June 13, 2024 the appointment of Mr. Stephen Friscia, a veteran investor, to the board of directors. Dr. Glass is board certified in internal medicine, pulmonary and critical care medicine, with a focus in inflammatory diseases and immunopathology.

His biopharmaceutical career spans 35 years across diverse life sciences industries and fields, from broad-ranging executive positions at top ten pharmaceutical companies, to founding, leading and funding start-ups and early-stage biopharma companies. As a long-term investor in the healthcare sector, Dr. Glass is a founder and principal of Medpro Investors. He is a long-term consultant and regulatory representative for company and university engagement with the FDA and international regulatory counterparts, and he currently serves on the American Lung Association?s Scientific Advisory Committee.

Dr. Glass holds an extensive and successful track record in leading companies through FDA regulatory pathways from early research and development to late-stage trials and market commercialization. His career highlights include 5 new drug applications (NDAs) and marketing authorization applications (MAAs), 7 pre-NDA meetings including international counterparts, 12 End of Phase 2 (EOP2) meetings with FDA, and more than 80 investigational new drug applications (INDs). Mr. Friscia is the manager and co-founder of Kipps Capital.

Previously, Mr. Friscia was a managing director and portfolio manager for multiple institutional investment and asset management firms, with several focused in small and mid-cap value equities, including Iridian Asset Management LLC, MacKay Shields LLC, Bear Stearns Asset Management Inc., John A. Levin & Co., Inc., and Evergreen Investments LLC (Wachovia Corporation).